Cystine and theanine for chemoradiotherapy-induced esophagitis in non-small cell lung cancer: a prospective observational study
Supportive Care in Cancer · 2024
DOI: 10.1007/s00520-024-08613-0 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Misato Kariya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition Support Team, Kobe Minimally Invasive Cancer, Kobe, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Esophagitis, Chemoradiotherapy, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Although several potential radioprotectants have been explored, radiation esophagitis is still difficult to control. Further development of supportive therapies is required. Our purpose was to investigate the efficacy and safety of cystine and theanine for esophagitis in non-small cell lung cancer (NSCLC) patients undergoing chemoradiotherapy (CRT). METHODS: This study is a prospective observational study. The participants were recruited from unresectable locally advanced NSCLC who had scheduled to receive weekly paclitaxel or nab-paclitaxel/carboplatin plus radiation therapy (60 Gy in 30 fractions) for 6 weeks. They took an oral amino acid supplement containing 700 mg cystine and 280 mg theanine once daily regardless of CRT timing from the start of CRT until completion. The primary endpoint was the incidence of any grade esophagitis. The secondary endpoints were quality of life (QoL) and adverse events (AEs). RESULTS: A total of 26 patients were evaluated. All participants completed 60 Gy of RT in 30 fractions. The overall incidence of esophagitis was 73%; however, no ≥ grade 3 was reported. There were no AEs likely to be related to cystine and theanine. The mean EuroQoL 5-Dimension 5-Level health index score before and after chemoradiotherapy was 0.952 ± 0.0591 and 0.952 ± 0.0515 (P = 0.89), and the mean Visual Analogue Scale scores before and after treatment were 67.9 ± 15.4 and 79.4 ± 13.2 (P = 0.0047), respectively. CONCLUSION: Our study showed no severe esophagitis, any AEs, nor QoL decrease in NSCLC patients receiving CRT. Cystine and theanine are potentially effective to reduce severe CRT-induced esophagitis. TRIAL REGISTRATION: UMIN000052622, 26 October 2023, retrospectively registered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition Support Team, Kobe Minimally Invasive Cancer, Kobe, Japan.
- Department of Pharmacy, Kobe Minimally Invasive Cancer Center, Kobe, Japan.
- Department of Pharmacy, Kobe University Hospital, Kobe, Japan.
- Department of Gastroenterology, Kobe Minimally Invasive Cancer Center, Kobe, Japan.
- Department of Nursing, Kobe Minimally Invasive Cancer Center, Kobe, Japan.
- Department of Nutrition, Kobe Minimally Invasive Cancer Center, Kobe, Japan.
Zitieren
APA
Kariya, M., Yamamoto, K., Kawamura, A., Tanizaki, S., Ueda, K., Sai, K., & Hata, A. (2024). Cystine and theanine for chemoradiotherapy-induced esophagitis in non-small cell lung cancer: a prospective observational study. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-08613-0
Vancouver
Kariya M, Yamamoto K, Kawamura A, Tanizaki S, Ueda K, Sai K, et al. Cystine and theanine for chemoradiotherapy-induced esophagitis in non-small cell lung cancer: a prospective observational study. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-08613-0
BibTeX
@article{Kariya2024,
author = {Kariya, Misato and Yamamoto, Kazuhiro and Kawamura, Akira and Tanizaki, Shiho and Ueda, Keiko and Sai, Kastuko and Hata, Akito},
title = {Cystine and theanine for chemoradiotherapy-induced esophagitis in non-small cell lung cancer: a prospective observational study},
journal = {Supportive Care in Cancer},
year = {2024},
doi = {10.1007/s00520-024-08613-0}
}
EUVIMED